Yes, AIDS is very much still a thing. Approximately 40.8 million people worldwide were living with HIV at the end of 2024, and 630,000 people died from HIV-related causes that year alone. What has changed dramatically is how treatable the virus is. A person diagnosed with HIV today who starts treatment early can expect to live decades longer than someone diagnosed in the 1990s, and effective medication can reduce the virus to undetectable levels, making sexual transmission impossible. But the epidemic is far from over, and certain communities bear a disproportionate burden.
What HIV and AIDS Actually Mean Today
HIV (the virus) and AIDS (the most advanced stage of infection) are not the same thing, and that distinction matters more now than ever. AIDS is diagnosed when a person’s immune cell count drops to 200 or below per cubic millimeter of blood, roughly a fifth of the normal minimum. At that point, the immune system is severely compromised and vulnerable to infections that a healthy body would easily fight off.
Most people with HIV in wealthy countries never develop AIDS, because modern treatment keeps the virus suppressed long before the immune system deteriorates that far. The term “AIDS” is used less frequently in clinical settings than it once was. Instead, clinicians refer to stages of HIV infection, with AIDS being “stage 3.” But in parts of the world where testing and treatment remain limited, AIDS-related illness and death continue at alarming rates.
How Treatment Changed the Picture
Antiretroviral therapy, the daily medication regimen that suppresses HIV, has transformed the virus from a death sentence into a manageable chronic condition. Data from a large study tracking outcomes from 2013 to 2023 found that the life expectancy of a 20-year-old starting treatment rose from about 30 additional years to nearly 46 additional years over that decade. The gap between their life expectancy and that of the general population shrank from roughly 27 years to about 15. That gap continues to narrow as treatment improves and people start medication earlier.
One of the most significant breakthroughs in HIV science is the concept known as U=U: Undetectable equals Untransmittable. When a person takes their medication consistently and their viral load drops below detectable levels on a blood test, they cannot sexually transmit the virus. This isn’t a theoretical estimate. A major clinical trial tracked over 1,600 couples for 10 years and found zero transmissions when the HIV-positive partner maintained viral suppression. Follow-up studies confirmed the same results for male-male couples. This finding has reshaped both treatment motivation and the stigma surrounding HIV.
People Are Still Getting Infected
In the United States, there were 39,201 new HIV diagnoses in 2023 among people aged 13 and older. That’s a meaningful number, and the infections are concentrated in specific communities. Two-thirds of new diagnoses (66%) were attributed to male-to-male sexual contact. Black and African American individuals accounted for 38% of new diagnoses despite making up about 13% of the population, with a diagnosis rate of 41.9 per 100,000, roughly three times the rate among Hispanic or Latino individuals and more than 10 times the rate among white individuals.
The geographic pattern is equally stark. More than half of all new U.S. diagnoses in 2023 occurred in the South, which had the highest regional diagnosis rate at 18.4 per 100,000. Young adults aged 25 to 34 made up the single largest age group, accounting for 37% of new diagnoses. Among women specifically, Black and African American women accounted for half of all female diagnoses while representing only 13% of the female population. Their diagnosis rate was 11 times that of white women.
These numbers reflect deep inequities in healthcare access, stigma, poverty, and education rather than biological differences. The virus doesn’t discriminate, but social conditions shape who gets tested, who gets treated, and who falls through the cracks.
Prevention Tools That Work
Beyond treatment, prevention has advanced considerably. PrEP, a medication taken by HIV-negative individuals to prevent infection, reduces the risk of getting HIV from sex by about 99% when taken as prescribed. For people who inject drugs, PrEP pills reduce risk by at least 74%. PrEP is available as a daily pill or, more recently, as a long-acting injection given every two months.
Testing has also improved. Modern lab-based tests that look for both viral proteins and antibodies can detect HIV infection as early as 18 to 45 days after exposure when using blood drawn from a vein. Rapid finger-stick versions of the same test have a window of 18 to 90 days. No test can detect HIV immediately after exposure, so timing matters, but the days of waiting months for a reliable result are largely over.
Why the Epidemic Persists
If treatment prevents transmission, PrEP prevents infection, and testing catches the virus early, why are hundreds of thousands of people still dying every year? The answer is access. The 630,000 global deaths in 2024 are overwhelmingly concentrated in low- and middle-income countries, particularly in sub-Saharan Africa and parts of Southeast Asia, where many people with HIV either don’t know their status or can’t access consistent treatment. Stigma remains a powerful barrier. In many countries, laws criminalizing same-sex relationships or drug use push the people most at risk away from testing and care.
Even in the United States, gaps persist. Not everyone diagnosed with HIV is linked to care, and not everyone in care achieves viral suppression. Young people, people experiencing homelessness, and communities in the rural South face particular challenges in accessing and staying on treatment. The tools to end the epidemic exist. The infrastructure and political will to deliver them universally do not, at least not yet.
No Vaccine, No Cure
Despite decades of effort, there is no approved HIV vaccine. Several candidates are in early-phase clinical trials (Phase 1 and Phase 2), but none has reached the large-scale Phase 3 trials needed to prove effectiveness. HIV mutates rapidly and attacks the very immune cells that would normally fight it off, making vaccine development uniquely difficult.
A handful of individuals have been functionally cured through stem cell transplants for cancer, but this approach is far too risky and complex to serve as a general treatment. Researchers are actively working toward a cure, though the Treatment Action Group, which tracks these trials, notes that none of the current studies is expected to produce one. For now, daily medication remains the standard of care, and it works remarkably well for those who can access it.